Login / Signup

Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma.

Karisa C SchreckStrowd ReLouis Burt NaborsBenjamin M EllingsonMichael ChangSze Kiat TanZied AbdullaevRust TurakulovKenneth D AldapeNeeraja DandaSerena DesideriJoy FisherMichaella IacoboniTrisha SurakusMichelle A RudekChetan BettegowdaStuart A GrossmanXiaobu Ye
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Encorafenib and binimetinib exhibit positive tumor responses in patients with recurrent BRAF-V600E mutant HGG in this small series, warranting therapeutic consideration. Although toxicity remains a concern for BRAF-targeted therapies, no new safety signal was observed in these patients.
Keyphrases
  • wild type
  • high grade
  • metastatic colorectal cancer
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • oxidative stress
  • low grade